A Phase II Randomised Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy-Naive Hormone-Refractory Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2014
At a glance
- Drugs Vandetanib (Primary) ; Bicalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 28 Mar 2014 Primary endpoint 'Prostate-specific-antigen-response-rate' has not been met.
- 28 Mar 2014 Results published in the Investigational New Drugs.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History